ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer
Despite initial benefits in treating HER2-positive breast cancer patients with lapatinib, resistance is prevalent. Here the authors show that lapatinib resistance can be ascribed to mTOR-mediated re-activation of ERRα and to the consequent induction of a metabolic adaptation.
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2016-07-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/ncomms12156 |